Abstract
Chronic kidney disease (CKD) is a common complex condition associated with significant morbidity and mortality worldwide. Early detection is critical for effective prevention of disease progression. While polygenic prediction could enhance screening, current approaches have not been optimized for ancestrally diverse populations. We developed and validated a genome-wide polygenic score (GPS) for CKD (defined by eGFR <60 mL/min/1.73m²) by combining common variant association statistics with APOL1 risk genotypes. The score was optimized using UK Biobank data and validated across 15 independent cohorts encompassing European, African, Asian, and Hispanic/Latinx ancestries. Our results demonstrate reproducible performance, with the top 2% of the GPS distribution associated with a nearly 3-fold increased risk of CKD across all groups—a level of risk equivalent to a positive family history. This score provides a framework for clinically meaningful risk stratification across diverse global populations.
Introduction
Chronic Kidney Disease (CKD) represents a major global health burden, yet early detection remains a significant clinical challenge. While genetic factors are known to contribute substantially to CKD risk, most existing Polygenic Risk Scores (PRS) suffer from a "diversity gap." Because these scores are primarily trained on datasets of European ancestry, their predictive accuracy often diminishes when applied to other ancestral groups.
Furthermore, for individuals of African ancestry, CKD risk is heavily influenced by specific high-impact variants in the APOL1 gene. Standard genome-wide association studies (GWAS) often fail to capture these effects because the variants are rare in non-African populations. This study addresses these limitations by developing a "universal" genome-wide polygenic score (GPS) that integrates broad genomic signals with ancestry-specific risk factors to ensure equitable predictive power.
Methodology
The researchers developed a GPS that synthesizes two distinct genetic signals:
- Broad Polygenic Signal: Utilizing summary statistics from a massive GWAS of over 765,000 individuals, the score captures thousands of common variants associated with the estimated glomerular filtration rate (eGFR), a standard proxy for kidney function.
- High-Impact APOL1 Signal: The model specifically integrates the "recessive model" of APOL1 risk (carrying two risk alleles: G1G1, G2G2, or G1G2), which is a primary driver of kidney disease in African and admixed populations.
To ensure the score's utility across different groups, the authors implemented two post-hoc ancestry adjustment strategies using the 1000 Genomes Project as a reference. By adjusting for mean and variance, they established a single, standardized "high-risk" threshold applicable regardless of an individual's continental ancestry.
Data and Validation
The study's robustness is supported by an extensive array of genomic resources:
- Optimization: The polygenic component was optimized using 70% of the UK Biobank (UKBB) European participants (~280,000 individuals), while APOL1 weighting was derived from UKBB African-ancestry participants.
- Validation: The score was tested in 15 independent cohorts totaling over 170,000 individuals, including eMERGE-III, BioMe Biobank, and specialized studies such as REGARDS, HyperGEN, and GenHAT.
Key Insights
The Additive Nature of Risk
A critical finding of the study is that APOL1 risk and general polygenic risk are additive. The researchers found no significant interaction between the two (P=0.29), meaning they contribute to disease risk independently. Consequently, an individual may be at high risk due to their APOL1 status, a high polygenic background, or a combination of both.
Baseline Polygenic Differences
Even when excluding APOL1 variants, individuals of African ancestry exhibited a significantly higher average polygenic risk score for CKD compared to other groups. This suggests that the higher prevalence of CKD in African American populations is driven by both high-impact variants and a higher "background" of common risk alleles.
Clinical Actionability
The study focused on the top 2% of the GPS distribution as a high-risk tier. Across all ancestries, this group faced a ~3x increased risk of CKD. In clinical practice, this magnitude of risk is considered highly actionable, as it mirrors the risk level associated with a strong family history of kidney disease.
Results and Performance
The GPS demonstrated consistent and reproducible performance across all 15 testing cohorts. The disease Odds Ratio (OR) per standard deviation of the score was:
- European: 1.49
- African: 1.32
- Asian: 1.59
- Hispanic/Latinx: 1.42
For those in the top 2% of the GPS, the risk increase was stark: 3.09x for Europeans, 2.66x for Africans, 2.95x for Asians, and 4.27x for Hispanic/Latinx cohorts. Notably, in Hispanic/Latinx cohorts, the inclusion of APOL1 improved the score's performance, likely due to African ancestral segments within those admixed genomes.
Limitations and Future Directions
While this GPS represents a significant step toward equitable genomic medicine, some limitations remain. The underlying GWAS data is still 75% European, and larger non-European GWAS are necessary to further refine allelic weights. Additionally, the score relies on eGFR—a biomarker that can be influenced by non-genetic factors like diet and muscle mass—rather than biopsy-confirmed disease. Finally, prospective clinical trials are required to demonstrate that implementing this GPS in a clinical setting leads to improved patient outcomes and more effective early interventions.
Summary updated